An Observational Study on Assessing the Safety and Efficacy of Tenecteplase for Door-To-Needle Time Acute Ischemic Stroke Patients

Background: Stroke is a significant burden in India which is a leading cause of death globally. This study aimed to evaluate the Safety and Efficacy of Tenecteplase for Acute Ischemic Stroke patients who arrived within 3.5 hr of symptom onset. Materials and Methods: The observational study was conducted from March 2023 to August 2023 at a multi-specialty hospital with 38 patients. Data were collected on demographics, medical history and various scales to assess stroke severity and recovery. Tenecteplase was administered at a dose of 0.4 mg per kg and patients were monitored clinically before and after thrombolysis, with follow-ups at 24 hr and 1 month. Results: The study found to have a higher incidence of stroke among males, with the age group being 56-65 years. Among the patients, most of the patients were smokers. Significant improvements were observed in the maximum number of patients, who scored 1-4 and 0 on the National Institute of Health Stroke Scale within 24 hr and 1 month respectively. The Modified Ranking Scale indicated that most of the patients reached the score of 2 and 0 within 24 hr and one month respectively. Muscle strength improvements were noted after 1 month using a Medical Research Council score. Conclusion: Tenecteplase shows a stronger safety profile and is efficacious in treating Acute Ischemic Stroke patients had 3.5 hr of symptom onset which highlights the effective treatment option, promoting better recovery and reducing morbidity and mortality rates.